References
- Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181–192.
- Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, Catalano PM, Morris CD. Pregnancy outcomes in healthy nulliparas who developed hypertension, Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000;95:24–28.
- Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract 2007;106:c72–c81.
- Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481 e1–7.
- Stella CL, Sibai BM. Preeclampsia: diagnosis and management of the atypical presentation. J Matern Fetal Neonatal Med 2006;19:381–386.
- Kamen B, Karwal MA, Yankowitz J. Hemolysis and elevated transaminases imitating severe preeclampsia. Obstet Gynecol 2009;113:545–547.
- Bdolah Y, Lam C, Rajakumar A, et al Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198:e421–e426.
- Chaiworapongsa T, Romero R, Kim YM, et al Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18.
- Levine RJ, Lam C, Qian C, et al Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005.
- Levine RJ, Maynard SE, Qian C, et al Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
- Levine RJ, Thadhani R, Qian C, et al Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77–85.
- Maynard SE, Min JY, Merchan J, et al Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
- Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266–1274.
- Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:28 e21–e26.
- Shibata E, Rajakumar A, Powers RW, et al Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895–4903.
- Venkatesha S, Toporsian M, Lam C, et al Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–649.
- Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368–1374.
- Diagnosis and management of preeclampsia and eclampsia: American College of Obstetrics and Gynecology practice bulletin 2002;33:1–9.
- Thrombocytopenia in pregnancy: American College of Obstetrics and Gynecology Practice Bulletin 1999;6:1–12.
- Levine RJ, Hauth JC, Curet LB, et al Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69–76.
- Burrows RF, Kelton JG. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. Am J Obstet Gynecol 1990;162:731–734.